When outcomes from R&D are addressed, new products are certainly the first outputs that are thought of as being produced by pharmaceutical and biotechnology companies. New products often are prescribed preferentially by physicians for the mitigation of disease and improvement of patient care because of their novel features over existing treatments. These new products will be the primary driver of innovations in health care, research advances, profitability, and business success for a company. However, many other important outcomes are needed routinely to be delivered by the R&D division and need support from all the rest of the company in order for the company to achieve four goals: demonstrate their scientific and medical prowess and productivity, meet the needs of the public and health care community for the best products used optimally, meet the needs of the shareholders, and sustain the company’s research edge against the competition.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Guy P. Rising to the productivity challenge. A strategic framework for biopharma. Boston Consulting Group. July 2004.
Lawyer P, Kirstein A, Yabuki H, Gjaja M, Kush D. High science: a best-practice formula for driving innovation. In Vivo The Business & Medicine Report 2004;22(4):1–12 (BCG authors).
Ernst & Young. Resurgence: The Americas perspective. 2004.
Ernst & Young. Progressions. Global Pharmaceutical Report 2004.
Lamberti MJ (Ed). An Industry in Evolution, 4th ed. Thomson, CenterWatch. 2003.
Anonymous. Report to the Nation 2003, Improving Public Health through Human Drugs. Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services.
Vander Walde L, Choi K, Higgins J. Health Care Industry Market Update. Pharmaceuticals. Centers for Medicare and Medicaid Services. Department of Health and Human Services. January 2003, 1–52.
Anonymous. Health Care in America. Trends in Utilization. Centers for Disease Control. Department of Health Human Services. 2002, 1–90.
Lahteenmaki R, Baker M. Public biotechnology 2003—the numbers. Nature Biotechnology 2004;22(6):665–670.
Booth B, Zemmell R. Prospects for productivity. Nature Reviews Drug Discovery 2004;3(5):451–456.
Rawlins MD. Cutting the cost of drug development. Nature Reviews Drug Discovery 2004;3(4):360–364.
15th annual report top 50 pharmaceutical companies. Med Ad News 2003;22(9):4–19.
Sellers LJ (ed). Our 5th annual report of the world's top 50 pharma companies. Pharmaceutical Executive 2004;24(5):60–70.
Trombetta B. Industry audit & “fab four” companies of the year. Pharmaceutical Executive 2003;23(9):38–64.
From pipeline to market 2004. Areas of interest. R&D Directions 2004;10(6):8–18.
King J. Advances in medicine.100 great investigational drugs. R&D Directions 2004;10(3):31–51.
Engel S. How to manage a winning pipeline. R&D Directions 2002;(2):36–41.
Anonymous. Profile pharmaceutical industry 2004, Focus on innovation. PhRMA, 2004.
Anonymous. PhRMA. Industry profile 2003. Prescription medicines 25 years ago and today: changing trends, enduring needs. 1–81.
Ernst & Young. The economic contributions of the biotechnology industry to the US economy. May 2000, Biotechnology Industry Organization.
Tufts Center for Study of Drug Development. Outlook 2005;1–5.
Tufts CSDD. Outlook 2004;1–8.
Tufts CSDD. Outlook 2003;1–8.
Tufts CSDD. Outlook 2002;1–5.
Tufts CSDD. Outlook 2001;1–5.
Matthieu M (ed.). Parexel's Pharmaceutical R&D Statistical Sourcebook 2005–2006. Parexel Publishing, Boston, MA. 2005.
Anonymous. Health, United States, 2004. National Center for Health Statistics. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.
Edwards MG, Murray F. Yu R. Value creation and sharing among universities, biotechnology and pharma. Nature Biotechnology 2003;21(6):618–624.
Resnick JT. Reputation the inside story. Pharmaceutical Executive 2003;23(6):40–48.
Gasorek DW, Resnick JT. The rise and fall of pharma reputations. Pharmaceutical Executive 2005;25(2):76–83.
Maggon K. The ten billion dollar molecule. Pharmaceutical Executive 2003;23(11):60–68.
Bogan C, Wang D. Launching a blockbuster. Pharmaceutical Executive 2000;20(8):96–104.
Booth B, Zemmel R. Quest for the best. Nature Reviews Drug Discovery 2003;2(10):838–841.
King J. Today's drug discovery unlocking greater potential. R&D Directions 2004;10(2):28–39.
Lindsay MA. Target discovery. Nature Reviews Drug Discovery 2003;2(10):831–837.
Lombardino JG, Lowe III JA. The role of the medicinal chemist in drug discovery—then and now. Nature Reviews Drug Discovery 2004;3(10):853–862.
Product failures.
Garaud J-J. The most diversified development pipeline, innovation, focus, productivity. R&D Directions 2004 Drug Development Summit, How to Build and Maintain a Winning Pipeline. Feb. 8–11, 2004.
Bellucci NM. The top 10 pipelines. Novartis: most productive and strongest primary care pipeline. Stroing and steady. R&D Directions 2005;11(1):50–53.
Amgen Web site (amgen.com), December 2004.
Bellucci NM. Top 10 pipelines. Amgen: most advanced pipeline/best biotechnology pipeline. R&D Directions 2005;11(1):32–35.
Bellucci NM. Top 10 pipelines. R&D Directions 2005;11(1): 32–66.
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery 2004;3(8):673–683.
Frei P, Leleux B. Valuation—what you need to know. Nature Biotechnology 2004;22(8):1049–1051.
Tollman P, Goodall S, Ringel M. The gentle art of licensing. Rising to the productivity challenge in biopharma R&D. Boston Consulting Group. July 2004.
Arnold K, Coia A, Saywell S, Smith T, Minick S, Loffler A. Value drivers in licensing deals. Nature Biotechnology 2002;20(11):1085–1089.
Featherstone J, Renfrey S. From the analyst's couch. The licensing gamble: raising the stakes. Nature Reviews Drug Discovery 2004;3(2):107–108.
Webber PM. Protecting your inventions: the patent system. Nature Reviews Drug Discovery 2003;2(10):823–830.
Rubinger B, Davis H. Protecting IP throughout the product lifecycle. Pharmaceutical Executive 2003;23(8):40–48.
Steffe EK, Shea Jr TJ. Protecting innovation in biotechnology startups. Nature Biotechnology Supplement 21:BE51-BE53, 2003.
Lam LD. Biotech+Pharma dangerous liaisons. Pharmaceutical Executive 2004;24(5):72–80.
Engel S. Drug-discovery companies aim for commercialization. Good leads good medicine. R&D Directions 2002;8(7):34–42.
Lam MD. Biotech+pharma. Why alliances fail. Pharmaceutical Executive 2004;24(6):56–66.
Ansell J. The billion dollar pyramid. Megamergers' greatest challenge. Pharmaceutical Executive 2000;(8):64–72.
Bogan C, Symmers K. Marriages made in heaven. Pharmaceutical Executive 2001;(1):52–60.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Evens, R.P. (2007). R&D Outcomes. In: Evens, R.P. (eds) Drug and Biological Development. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69094-0_3
Download citation
DOI: https://doi.org/10.1007/978-0-387-69094-0_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-32978-9
Online ISBN: 978-0-387-69094-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)